DAY ONE BIOPHARMACEUTICALS DAWN 深 沪
已收盘 08-01 16:00:00 美东时间
6.65
-0.060
-0.89%
华盛通- 最 高6.72
- 今 开6.65
- 成交量 105.27万股
- 最 低 6.425
- 昨 收 6.71
- 总市值 6.72亿
- 52周最高 16.76
- 市盈率 静 --
- 换手率 1.04%
- 52周最低 6.08
- 委 比 -25.06%
- 总股本 1.01亿
- 历史最高 28.699
- 量 比 0.78
- 振 幅 4.40%
- 历史最低 5.44
- 每 手 1
- 风险率 1.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025
Day One Biopharmaceuticals (Nasdaq: DAWN) will host a live conference call and webcast on August 5, 2025, at 4:30 p.m. ET to discuss Q2 2025 financial results and corporate progress. The webcast will be available on Day One's Events page and archived for 30 days. The company, headquartered in Brisbane, California, focuses on developing targeted therapies for life-threatening diseases, particularly pediatric cancer, with a pipeline including tovor...
07-22 12:30
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
Dr. Michael Vasconcelles, with over 25 years of oncology experience, joins Day One Biopharmaceuticals as Head of Research & Development. He aims to drive pipeline creation and execution, advancing targeted therapies for patients with life-threatening diseases. Day One specializes in pediatric cancer treatments, and Vasconcelles’ background includes leading global oncology projects at major companies like ImmunoGen, Flatiron Health, and Takeda. Hi...
06-10 12:30
恒瑞ASCO“核爆级”输出，隐藏哪些潜在大药？
（转自：药剂Talks） 恒瑞医药又在国际舞台上亮剑了。 美国临床肿瘤学会（ASCO）年会是全球规模最大、学术水平最高且最具权威性的临床肿瘤学盛会，吸引了全球...
06-02 08:53
美股大行评级 | 潜在涨幅105.34%！Amylyx Pharmaceuticals获Leerink Partners升目标价至10美元，上调至"跑赢大市"评级
每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。
05-08 08:45
Needham Maintains Buy on Day One Biopharmaceutical, Lowers Price Target to $27
Needham analyst Ami Fadia maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and lowers the price target from $30 to $27.
05-07 20:19
京东京麦服务市场去年商家使用量增长近40%，120家服务商获2025“京卓越”奖
4月29日,2025年京东服务商生态合作伙伴大会在北京举行,吸引了来自全国的500多家服务商踊跃参与。 为了表彰过去一年间在交易规模、服务质量、履约效率...
05-03 20:03
美股大行评级 | 潜在涨幅117.92%！Proficient Auto Logistics获Stifel升目标价至18美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1114836103639961600.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Stifel：维持Proficient Auto Logistics(PAL)"买入"评级，目标价从17美元升至18美元</p> <p>• Craig-Hallum：上调Sportsman's Warehouse(SPWH
04-04 15:42
HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $36 Price Target
HC Wainwright & Co. analyst Andres Maldonado reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $36 price target.
04-03 18:43
美股大行评级 | 潜在涨幅592.64%！Larimar Therapeutics获HC Wainwright升目标价至16美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1111574370732224512.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Larimar Therapeutics(LRMR)"买入"评级，目标价从15美元升至16美元</p> <p>• HC Wainwright & Co.：维持Au
03-26 08:45
美股大行评级 | 富国银行：维持艾伯维"超配"评级，目标价从210美元升至240美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1104327819967434752.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Syndax制药(SNDX)"超配"评级，目标价从35美元升至39美元</p> <p>• 摩根大通：维持AnaptysBio(ANAB)"超配"评级，目标价从36美元升至42美元</p> <p>• 摩根大通
03-06 11:20
